Cationic Steroidal Antimicrobial Prodrugs via Cleavable Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cationic steroidal antimicrobial (CSA) compounds face challenges in stability, solubility, and chemical reactivity, which affect their therapeutic efficacy and bioavailability when used as antimicrobial agents.
Innovation Solution
Development of CSA prodrug compositions that include pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs with cleavable groups, allowing for conversion to an active form under physiological conditions or during pharmaceutical formulation, enhancing stability, solubility, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CSA compounds are used directly as antimicrobial agents, then antimicrobial efficacy is achieved, but stability and chemical reactivity are insufficient
Solution Approach 1:
The CSA compound is converted to a prodrug form before administration, where the active antimicrobial agent is protected in an inactive or less active form. This preliminary transformation allows the compound to be stabilized for storage and administration, then activated in vivo through metabolic processes or physiological conditions to achieve the desired antimicrobial efficacy.
Solution Approach 2:
A prodrug intermediate structure is introduced between the stable storage form and the active antimicrobial form. This intermediary prodrug structure allows the compound to be administered in a stable form while containing the latent active agent that can be released under specific physiological conditions, thus bridging the gap between stability and reactivity requirements.
2Reliability
If CSA compounds are used directly, then antimicrobial activity is present, but solubility is limited affecting bioavailability
Solution Approach 1:
The prodrug modification changes the physicochemical parameters of the CSA compound, specifically improving solubility characteristics. By altering the molecular structure through prodrug chemistry (such as adding solubilizing groups or modifying ionization properties), the compound achieves better solubility in physiological fluids, thereby improving bioavailability while maintaining the core antimicrobial activity upon activation.
3Speed
If CSA compounds are administered in active form, then immediate antimicrobial effect is achieved, but therapeutic window is limited and half-life is short
Solution Approach 1:
The prodrug is administered in advance in an inactive form that is stable and has improved pharmacokinetic properties. Upon administration, it is converted to the active CSA compound in vivo, providing a sustained release of the active agent. This preliminary action extends the therapeutic window and maintains effective concentrations for longer durations compared to direct administration of the active compound.
Solution Approach 2:
The prodrug system introduces dynamic transformation from inactive to active form within the body. This dynamic conversion allows the compound to adapt its state based on physiological conditions, enabling controlled activation and sustained presence of the active antimicrobial agent, thereby extending the duration of action and therapeutic window.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CSA prodrugs exhibit improved bioavailability, extended therapeutic window, increased half-life, and sustained effective concentrations, addressing stability and reactivity issues while maintaining antimicrobial efficacy.
Implementation Method 1
The one or more cleavable groups (B) include protecting groups (e.g., amino protecting groups) that cleave from the CSA compound under physiological conditions and/or during the preparation of a pharmaceutical formulation.
Data Source
AI summary
Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein.